Stevens Capital Management LP Sells 2,873 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Stevens Capital Management LP lessened its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 76.3% during the 4th quarter, HoldingsChannel reports. The firm owned 890 shares of the medical equipment provider’s stock after selling 2,873 shares during the period. Stevens Capital Management LP’s holdings in Intuitive Surgical were worth $300,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ISRG. WCM Investment Management LLC purchased a new stake in Intuitive Surgical in the fourth quarter worth about $575,536,000. International Assets Investment Management LLC lifted its stake in Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after acquiring an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd lifted its stake in Intuitive Surgical by 113.2% in the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after acquiring an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Intuitive Surgical in the third quarter worth about $178,667,000. Finally, Quadrature Capital Ltd lifted its stake in Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after acquiring an additional 280,480 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ISRG. Piper Sandler upped their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Wells Fargo & Company upped their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a report on Friday, January 19th. Barclays upped their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Truist Financial increased their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Finally, Royal Bank of Canada increased their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Myriam Curet sold 5,318 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at $110,456.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the transaction, the executive vice president now owns 298 shares in the company, valued at approximately $110,456.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Gary S. Guthart sold 24,325 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 249,418 shares of company stock valued at $96,300,959. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded up $2.21 during midday trading on Friday, reaching $375.33. 927,473 shares of the company’s stock were exchanged, compared to its average volume of 1,658,417. The firm’s 50 day simple moving average is $386.26 and its two-hundred day simple moving average is $345.39. The stock has a market cap of $133.13 billion, a price-to-earnings ratio of 67.75, a P/E/G ratio of 4.84 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 earnings per share. Equities research analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.